Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Media

PH

FDA Expands Methotrexate Indication to Included Children With Acute Lymphoblastic Leukemia

November 14th 2024November 1st 2024

Read More

ONC NEWS CENTRAL LOGO

FDA Expands Liquid Methotrexate Indication to Pediatric ALL Patients

April 29th 2025November 1st 2024

Read More

Shorla Oncology Lab

Shorla is building a global Irish pharma brand

July 18th 2025October 31st 2024

Read More

EY

EY Entrepreneur Of The Year

July 26th 2024

Read More

Shorla Oncology

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

February 20th 2025July 2nd 2024

Read More

FDA

FDA approves Shorla Oncology’s TEPYLUTE for cancer treatment

February 20th 2025July 2nd 2024

Read More

Photo

A Milestone for Shorla Oncology

April 22nd 2024

Read More

Logo

FDA Considers SH-201 for Treating Certain Leukemias and Cancers

April 22nd 2024

Read More

Oncology Live Logo

FDA Accepts NDA for SH-201 in Leukemia and Other Cancers

July 18th 2025April 22nd 2024

Read More

Older posts
Newer posts
Page1 Page2 Page3 Page4 … Page7
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.